NASDAQ · Biotechnology

ASLAN Pharmaceuticals Limited (ASLN) Stock

$0.60 -14.27% NASDAQ: ASLN Healthcare

ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders.

Valuation

MetricValue
Price$0.60
Market Cap$777.12M
P/E Ratio-0.06
P/B Ratio-0.19
P/S Ratio64.76
EPS (TTM)$-10.76
52-Week High$17.04
52-Week Low$0.48
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE338.46%
ROA-179.56%
ROCE-379.93%
Gross Margin97.10%
Operating Margin-364.46%
Net Margin-368.50%
Debt/Equity-2.02
Current Ratio1.84

Annual Financials (USD)

Metric20192020202120222023
Revenue$3.0M$0$0$0$12.0M
Operating Profit$-46.0M$-16.0M$-34.0M$-48.0M$-44.0M
Net Profit$-47.0M$-18.0M$-35.0M$-51.0M$-44.0M
EPS$-29.00$-9.32$-10.64$-14.72$-10.76
Op Margin-1519.3%———-364.5%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$23.0M$16.0M$95.0M$61.0M$25.0M
Total Liabilities$24.0M$26.0M$37.0M$53.0M$38.0M
Cash$22.0M$14.0M$90.0M$57.0M$21.0M
Borrowings$18.0M$19.0M$31.0M$38.0M$27.0M

Latest News

OP Pohjola's President and Group CEO Timo Ritakallio has announced that he will retire on 1 July 2027 as specified in his executive contract GlobeNewswire · Jul 23, 2026 Tocvan Discovers New High-Grade At-Surface Silver-Gold Zone 900 m East of Pilot Facility at Gran Pilar Project ACCESS Newswire · Jul 23, 2026 Constellation Brands Shareholders Approve Directors, Pay and Incentive Plan at Annual Meeting MarketBeat · Jul 23, 2026 Eco (Atlantic) Oil and Gas Ltd Announces Audited Results for the Year Ended 31 March 2026 ACCESS Newswire · Jul 23, 2026 OP Corporate Bank plc's Half-year Financial Report 1 January–30 June 2026 GlobeNewswire · Jul 23, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-26.0M$-15.0M$-34.0M$-38.0M$-46.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$19.0M$7.0M$110.0M$5.0M$11.0M
Net Cash Flow$-7.0M$-8.0M$76.0M$-33.0M$-36.0M
Free Cash Flow$-26.0M$-15.0M$-34.0M$-38.0M$-46.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-19.86
FCF Yield-5.97%
Quick Ratio1.84
Interest Coverage-10.11
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.

ASLAN Pharmaceuticals Limited is headquartered in SG.

ASLAN Pharmaceuticals Limited (ASLN) stock trades at $0.60 with a market capitalization of $777.12M. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of -0.19, price-to-sales of 64.76. Over the past 52 weeks the stock has ranged between $0.48 and $17.04, and currently trades 96.5% below its 52-week high.

On profitability, ASLAN Pharmaceuticals Limited generates a return on equity (ROE) of 338.46% — well above the market average, a sign of a high-quality business, return on capital employed of -379.93%, an operating margin of -364.46%, a net profit margin of -368.50%.

Official website: aslanpharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides